Pieter Nel

Dr. Pieter Nel

Medical Microbiology & Immunology, Stellenbosch University, Stellenbosch, South Africa
+1
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
WDWentzel Bruce Dowling
Wentzel Bruce Dowling
AWAndrew Whitelaw
Andrew Whitelaw
PNPieter Nel
Pieter Nel
The Xpert MTB/Rif Ultra (Xpert Ultra; Cepheid, USA) has increased sensitivity compared with its predecessor (Gene Xpert), due to the addition of multicopy amplification targets and a novel trace call. The World Health Organization suggests that tuberculosis (TB) treatment should be initiated in HIV, paediatric, and extra-pulmonary TB patients with trace results. However, other factors such as previous TB disease may complicate the interpretation of trace results in high-burden TB settings. This study aimed to clarify the positive predictors for active TB disease in patients with trace results and to investigate if previous TB disease influences TB culture positivity. A retrospective descriptive study was performed on 290 patients with trace results, to determine what the positive predictors for active TB are by comparing clinical factors to TB culture. The key findings of this study were that extra-pulmonary TB samples (OR, 2.7; p=0.012), no previous TB disease (OR, 4.5; p=0.001) and symptoms suggestive of TB (OR, 6.4; p<0.001) are independent predictors for active TB disease. This study found readily available clinical predictors that can aid clinicians with TB management decisions in patients with trace results.

1 September 2022 in Paediatric Respiratory Reviews
Verified
Journal Article
Closed access
PGPierre Goussard
Pierre Goussard
EEErnst Eber
Ernst Eber
LMLunga Mfingwana
Lunga Mfingwana
PNPieter Nel
Pieter Nel
PSPawel Schubert
Pawel Schubert
CRCamilla le Roux
Camilla le Roux

22 December 2023 in African Journal of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
JHJessica S. Hurwitz
Jessica S. Hurwitz
MNMae Newton-Foot
Mae Newton-Foot
KZKristien Nel van Zyl
Kristien Nel van Zyl
PNPieter Nel
Pieter Nel
Background: Fosfomycin treatment of urinary tract infections is increasingly attractive due to escalating antibiotic resistance rates among urinary pathogens. Standard antibiotic susceptibility testing methods perform poorly for fosfomycin as there is poor correlation between susceptibility results and clinical outcomes in urinary pathogens other than Escherichia coli. Objective: We evaluated the performance of fosfomycin susceptibility testing in E. coli and Klebsiella pneumoniae to determine whether fosfomycin susceptibility is associated with molecular resistance mechanisms. Methods: Forty-six each of E. coli and K. pneumoniae clinical isolates were obtained from a tertiary hospital in South Africa, from 01 June 2017 to 31 January 2018. Agar dilution, disk diffusion, and gradient diffusion were performed and interpreted using the Clinical Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing guidelines. Molecular resistance mechanisms were identified by whole genome sequence analysis. Results: Disk diffusion and gradient diffusion were accurate alternatives for fosfomycin susceptibility testing in E. coli (98% categorical agreement), but not in K. pneumoniae (47% categorical agreement). All E. coli isolates contained at least one resistance mechanism, but only one isolate with a fosA gene was resistant. In K. pneumoniae, 63% (29/46) and 70% (32/46) of isolates were susceptible to fosfomycin, using Clinical Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing breakpoints, respectively, despite all isolates containing a fosA gene and a uhpT mutation. Conclusion: A better understanding of fosfomycin susceptibility and improved antibiotic susceptibility testing tools could improve diagnostic capability and clinical guidelines for fosfomycin treatment of urinary tract infections. What this study adds: This study highlights the importance of adhering to interpretive guidelines when performing antimicrobial susceptibility testing and the need for simplified, accurate and standardised susceptibility testing methodology and interpretation for fosfomycin in Enterobacterales organisms.

1 September 2022 in Paediatric Respiratory Reviews
Verified
Journal Article
Closed access
PGPierre Goussard
Pierre Goussard
EEErnst Eber
Ernst Eber
HRHelena Rabie
Helena Rabie
PNPieter Nel
Pieter Nel
PSPawel Schubert
Pawel Schubert

19 January 2022 in Southern African Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
LMLesedi B. Mosime
Lesedi B. Mosime
MNMae Newton-Foot
Mae Newton-Foot
PNPieter Nel
Pieter Nel
Ral fosfomycin is commonly used to treat uncomplicated urinary tract infections (UTI) and whilst resistance has been reported in many healthcare facilities in South Africa, the current prevalence remains unknown. This study investigated the prevalence and mechanisms of fosfomycin resistance amongst urinary pathogens in the Western Cape, South Africa. Of the 200 isolates collected during the study period (2019–2020), seven (3.5%) were fosfomycin resistant. Mutations in the glpT and uhpT transporter genes were the most common mechanism of resistance detected. These findings support the ongoing use of fosfomycin as an empiric antibiotic choice for the treatment of community-acquired UTI in this setting.

22 November 2019 in Southern African Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
PNPieter Nel
Pieter Nel
LRLauren A. Roberts
Lauren A. Roberts
RHRena Hoffmann
Rena Hoffmann
Background: Infections caused by carbapenemase-producing Enterobacteriaceae (CPE) have been increasing worldwide in recent years, but data regarding the prevalence and clinical significance of CPE colonisation in South Africa is not well documented. Local private hospital groups have implemented routine screening programmes for selected high-risk patients as endorsed by the South African Society for Clinical Microbiology. This practice is not routinely performed in the public sector. Methods: A point prevalence study was performed at Tygerberg Hospital (TBH) by screening patients of all the adult inpatient wards to investigate the current prevalence of CPE colonisation. Common risk factors associated with CPE colonisation were also investigated. Results: From a total of 439 patient samples collected, only one patient was colonised with a Klebsiella pneumoniae organism harbouring blaNDM-1. The identified patient had none of the common risk factors associated with CPE colonisation. Conclusion: Based on these findings, screening for CPE colonisation in adults on admission to TBH is currently not recommended.